Precirix platform allows the design and development of novel radiopharmaceuticals or targeted radionuclide therapies, a technology in which radionuclides are attached to ligands that direct them to their specific target on the cancer cell with exceptionally long tumor retention times. The radioactive payload is delivered, in a highly selective manner to the tumor, limiting radiation to the rest of the body.
Our technology platform facilitates development of single domain antibodies (sdAbs) for multiple targets, in combination with different isotopes and applicability in various settings.
CAMs combine the benefit of conventional mono-clonal antibodies and peptides
Peptide like properties include small size, high solubility, fast tumor penetration and rapid blood clearance
Monoclonal antibody like properties include high target specificity, high affinity, exceptional stability and long tumor retention
Direct cell killing and bystander effects
Target any extracellular tumor antigen
Short development timelines
Predictable process
Suitable for any radiometal
Therapeutic and diagnostic use
Alpha and beta emitters
High target specificity and affinity
Fast tissue penetration
Rapid blood clearance
CAM-FAP is our lead program. It is a single domain antibody construct that targets fibroblast activation protein alpha and is nearing IND readiness.
In addition to the lead program, the company has several molecules in the advanced pre-clinical stage including one targeting folate receptor alpha and several undisclosed targets.
| Hit | Lead | Ind enabling | Phase Ⅰ | Phase Ⅰ/Ⅱ | |
|---|---|---|---|---|---|
| CAM-FAP-Ac-225 FAP+ solid tumors incl. pdac, gastric |
|
|
|
||
| CAM-FAP-ga-68 Imaging FAP+ solid tumors |
|
|
|
||
| CAM-HER2-Pb-212 Undisclosed |
|
Orchestra Life Sciences
|
|||
| CAM-FR Ovarian |
|
|
|||
| CAM-TRT 1 Undisclosed |
|
||||
| CAM-TRT 2 Undisclosed |
|
||||
| CAM-TRT 3 Undisclosed |
|
The company has completed a phase 1 study to evaluate CAM-H2 in the treatment of patients with advanced/ metastatic HER-2 positive breast and gastroesophageal cancer with our without brain metastases.
This asset is phase 2 ready and available for partnering or out licensing. If interested in finding out more, please contact info@precirix.com.
Relevant literature
Presentations
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.